UROV News and Press, Urovant Sciences Ltd. From 05/19/20

Urovant Sciences (UROV) is a stock that just recently came onto my radar when I read Terry Chrisomalis' article here on Seeking Alpha. That led me to doing my own research and discounted cash flow analysis, and I came to much the same conclusion as Terry. Although nothing is ever a certainty...

52-Week Post Hoc Analysis Shows Vibegron Patients Had Statistically Significant, Sustained Reduction in UUI and Total Incontinence Episodes Compared to Active Control Urovant Sciences (Nasdaq: UROV) announced today that data from the vibegron EMPOWUR 52-week extension study ( NCT03...

Mr. Robinson will assume the role of President and CEO and continue as a Urovant Board Member Mr. Robinson’s deep experience in the urology and overactive bladder markets makes him ideally suited to succeed Keith Katkin as Urovant prepares for the potential approval and commerci...

Urovant Sciences ( UROV ) announced that the FDA had accepted its New Drug Application ((NDA)) for its drug vibegron for the treatment of patients with overactive bladder ((OAB)). The expected catalyst for the FDA to review the drug is not expected until the end of 2020, but the biotech ...

Urovant Sciences (Nasdaq: UROV) announced today that Chief Executive Officer Keith Katkin will give a presentation at 5:40 a.m. Pacific / 8:40 a.m. Eastern on Tuesday, March 3, 2020, at Cowen and Company’s 40th Annual Health Care Conference in Boston. A live, audio webcast for th...

Image source: The Motley Fool. Urovant Sciences Ltd   (NASDAQ: UROV) Q3 2019 Earnings Call Feb 13, 2020 , 4:30 p.m. ET Operator Continue reading

Urovant Sciences Ltd. (UROV) Q3 2019 Earnings Conference Call February 13, 2020 5:00 PM ET Company Participants Ryan Kubota – Executive Director of IR Keith Katkin – Chief Executive Officer Ajay Bansal – Chief Financial Officer Cornelia Haag-Molkenteller &#...

Urovant Sciences (NASDAQ: UROV ): Q3 GAAP EPS of -$1.36 misses by $0.41 . More news on: Urovant Sciences Ltd., Earnings news and commentary, Healthcare stocks news, Read more ...

Urovant Sciences (Nasdaq: UROV) today reported financial results for the 2019 third fiscal quarter ended December 31, 2019. Recent Business Highlights Submitted a New Drug Application for vibegron for the treatment of patients with overactive bladder to the U.S. Food and Drug A...

Urovant Sciences (Nasdaq: UROV) announced today that it will report 2019 third fiscal quarter financial results after the close of U.S. financial markets on Thursday, February 13, 2020. Management will host a conference call to discuss Urovant’s financial results at 1:30 p.m. Pac...